Events - Pharvaris N.V.

Upcoming Events

May 20, 2026 11:00 AM EDT

2026 RBC Capital Markets Global Healthcare Conference

Click for Webcast

Add to Outlook

Add to Google Calendar

May 28 - May 31, 2026

2026 Eastern Allergy Conference (EAC)

Add to Outlook

Add to Google Calendar

Jun 12 - Jun 15, 2026

European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026

Add to Outlook

Add to Google Calendar

Past Events

Feb 1 - Feb 5, 2026

Western Society of Allergy, Asthma & Immunology (WSAAI) 63rd Annual Scientific Session

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the Phase 2 CHAPTER-1 Open-Label Extension Study 221.7 KB

Dec 3, 2025 8:00 AM EST

Pharvaris Reports Topline RAPIDe-3 Data

Listen to webcast

Supporting Materials

RAPIDe-3 Topline Data Disclosure 1.4 MB

Dec 1 - Dec 2, 2025

2025 BSI Clinical Immunology Professional Network (BSI-CIPN) Conference

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study 226.1 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 329.8 KB

Nov 6 - Nov 10, 2025

American College of Allergy, Asthma, and Immunology (ACAAI) 2025 Annual Scientific Meeting

Supporting Materials

Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Hereditary Angioedema: CHAPTER-1 660.2 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: RAPIDe-2 Results 338.8 KB

Deucrictibant vs. Standard of Care in Hereditary Angioedema: A Propensity Score-Matched Analysis 237.9 KB

Durability of Response to Single Dose Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks 179.6 KB

Outcomes of Deucrictibant-Treated Upper Airway and Laryngeal Hereditary Angioedema Attacks: RAPIDe-2 Part A Results 229.3 KB

Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks 553.5 KB

Clinical Validation of a Kinin Biomarker Assay to Characterize Bradykinin-Mediated Angioedema 505.1 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: CHAPTER-1 Open-Label Extension 523 KB

Oct 24 - Oct 26, 2025

Japanese Society of Allergology (JSA)

Supporting Materials

Deucrictibant vs. Standard of Care in HAE 633.8 KB

Oral Deucrictibant XR Tablet for Prophylaxis of HAE Attacks: CHAPTER-3 Phase 3 Trial Design 888.3 KB

Oct 10 - Oct 12, 2025

2025 HAE International (HAEi) Regional Conference EMEA

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study 437 KB

Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Health-Related Quality of Life and Disease Control in Participants with Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study 551 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 300.3 KB

Durability of Response to a Single Dose of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks 292.2 KB

Efficacy and Safety of Oral Deucrictibant for Prophylaxis and On-Demand Treatment of Attacks in Acquired Angioedema with C1 Inhibitor Deficiency: CREAATE Phase 3 Trial Design 255.5 KB

Clinical Validation of a Novel Biomarker Assay to Characterize Bradykinin-Mediated Angioedema in Prospective and Biobank Plasma Samples 563.9 KB

Oct 3 - Oct 5, 2025

Joint XXXVII Italian Society of Allergology, Asthma, and Clinical Immunology (SIAAIC) National Congress and World Allergy Organization Congress (WAO)

Supporting Materials

Efficacy and Safety of Oral Deucrictibant for Prophylaxis and On-Demand Treatment of Attacks in Acquired Angioedema with C1 Inhibitor Deficiency: CREAATE Phase 3 Trial Design 185 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study 233.6 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 167.6 KB

Oct 2 - Oct 4, 2025

Deutscher Allergiekongress (DAK)

Supporting Materials

Durability of Response to a Single Dose of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks 1.4 MB

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 1.8 MB

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study 1.5 MB

Oct 1 - Oct 4, 2025

Spanish Society of Allergology and Clinical Immunology (SEAIC)

Supporting Materials

Acquired Angioedema Due to C1-Inhibitor Deficiency: Conceptual Model of Patient Experience and Assessment of Patient-Reported Outcome Measures 334.3 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for the Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 1 MB

Durability of Response to a Single Dose of Oral Deucrictibant for the On-Demand Treatment of Hereditary Angioedema Attacks 979.3 KB

Sep 26 - Sep 28, 2025

Consortium of Independent Immunology Clinics (CIIC) Fall 2025 Conference

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study and Post-hoc Analysis on Durability of Response to a Single Dose of Oral Deucrictibant 345.5 KB

Long-Term Safety, Efficacy and Sustained Therapeutic Exposure of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension and Results of a Pharmacokinetics Study in Healthy Volunteers 1.3 MB

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
…
Next page
Last page

Presentations

Latest Corporate Presentation